% | $
Quotes you view appear here for quick access.

ZIOPHARM Oncology, Inc. Message Board

  • markak1515 markak1515 Jan 29, 2010 11:49 AM Flag

    "The bottom line"

    from the R&R report:

    We view the results of the randomized Phase II PICASSO trial of palifosfamide in soft tissue sarcoma as very promising and as clear evidence of an active compound, and we believe that Ziopharm will attract a large partner interested in developing the compound, which could lead to the acquisition of the company. In addition, both darinaparsin and indibulin are promising, albeit earlystage, compounds, and their development is guided from among the leading physicians in the lymphoma and breast cancer space.

4.66+0.17(+3.79%)Jul 25 4:00 PMEDT